ArticleiScience2025
High-content imaging of primary chronic lymphocytic leukemia cells predicts patient cohorts with distinct cellular drug responses.
Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evaluation of a Novel Fluorescent Marker for Continuous Live Imaging of Preimplantation Embryos.Journal of developmental biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer precision medicine benefits from identifying biomarkers that can predict therapy response. However, within a population of chronic lymphocytic leukemia (CLL) patients, there is heterogeneity that is inherent to the disease and also between patients. This heterogeneity, usually explained at the level of genetic and epigenetic abnormalities, obscures conventional potential biomarkers. As an alternative, confocal microscopy of live primary CLL patient samples in a microenvironment model that mimics proliferation centers was used to identify morphological features that define cellular phenotypes that can be used as alternative biomarkers. Applying machine learning to micrographs of 133 patient samples revealed five stable patient clusters, not discernible by standard clinical methods. Within clusters, CLL patient samples responded similarly to drugs, suggesting that live cell imaging could be used to stratify patients and predict drug responses for rational treatment design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.